--- title: "FOSUN PHARMA CFO Chen Zhanyu resigns, former BeOne Medicines executive Huang Zhi takes over" type: "News" locale: "en" url: "https://longbridge.com/en/news/281756792.md" description: "FOSUN PHARMA announced that CFO Chen Zhanyu resigned due to adjustments in work arrangements, effective April 2, 2026, and will continue to serve as Senior Vice President after resignation. Huang Zhi will take over as CFO, starting from April 2, 2026. Huang Zhi joined FOSUN PHARMA in February 2026 and has held finance-related positions at BeOne Medicines and Novartis" datetime: "2026-04-06T12:01:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281756792.md) - [en](https://longbridge.com/en/news/281756792.md) - [zh-HK](https://longbridge.com/zh-HK/news/281756792.md) --- # FOSUN PHARMA CFO Chen Zhanyu resigns, former BeOne Medicines executive Huang Zhi takes over Leidi Network, April 6 FOSUN PHARMA (stock code: 600196) recently announced that the board of directors received a written resignation letter from Chen Zhanyu, who applied to resign from the position of Chief Financial Officer due to adjustments in work arrangements. The resignation is effective from April 2, 2026. After the resignation takes effect, Chen Zhanyu will continue to serve as the company's Senior Vice President. On April 2, 2026, upon the nomination of the company's Chief Executive Officer, the board of directors agreed to appoint Huang Zhi as the company's Senior Vice President and Chief Financial Officer, with a term starting from April 2, 2026, until the end of the current board's term. Huang Zhi, a permanent resident of the United States, joined FOSUN PHARMA (including FOSUN PHARMA and its holding subsidiaries/units, hereinafter the same) in February 2026 and currently serves as the company's Senior Vice President, Chief Financial Officer, and Co-President of the Innovative Drug Division. Before joining the group, Huang Zhi mainly engaged in finance-related work. From April 2007 to October 2020, he held various positions at Novartis AG (stock code: NVS.NYS), listed on the New York Stock Exchange, including Business Planning Analysis Manager for the U.S. Oncology Division, Financial Head for West China, Head of Business Processes and Controls for Greater China, Head of Business Planning and Analysis for Greater China, and Chief Financial Officer for South Korea. From October 2020 to February 2025, Huang Zhi served as Chief Financial Officer for Greater China at BeOne Medicines, Financial Head for the Asia-Pacific region (excluding China), Global Technology Operations Financial Head, and Financial Head of the Innovation Center. During this period, he served as Global Commercial Finance Head for BeOne Medicines from June 2023 to February 2025. From May 2025 to January 2026, Huang Zhi served as Senior Vice President of Global Corporate Development & Finance at Ascentage Pharma (stock code: 6855.HK, AAPG.NASDAQ). ——————————————— ### Related Stocks - [600196.CN](https://longbridge.com/en/quote/600196.CN.md) - [159929.CN](https://longbridge.com/en/quote/159929.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [516610.CN](https://longbridge.com/en/quote/516610.CN.md) - [688235.CN](https://longbridge.com/en/quote/688235.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [06160.HK](https://longbridge.com/en/quote/06160.HK.md) - [589720.CN](https://longbridge.com/en/quote/589720.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) ## Related News & Research - [BeOne Medicines Revamps Board and Committees Ahead of 2026 AGM](https://longbridge.com/en/news/283065000.md) - [Everest Medicines Announces Positive First-in-Human Data for Personalized mRNA Cancer Vaccine EVM16 at AACR 2026](https://longbridge.com/en/news/283616571.md) - [Sino Biopharm Unit LaNova Unveils Promising ADC Data at AACR 2026](https://longbridge.com/en/news/283566957.md) - [Fapon Biopharma Presents at AACR Annual Meeting 2026, Showcasing Core Technology Platforms and Advancing Pipeline](https://longbridge.com/en/news/283317853.md) - [Junshi Biosciences Shareholder Plans Up to 2% Stake Reduction](https://longbridge.com/en/news/283841816.md)